Frontiers in Immunology (Aug 2022)
Editorial: Innate immune cell therapy of cancer
- Natasha Khatwani,
- Natasha Khatwani,
- Natasha Khatwani,
- Natasha Khatwani,
- Rizwan Romee,
- Asha B. Pillai,
- Asha B. Pillai,
- Asha B. Pillai,
- Asha B. Pillai
Affiliations
- Natasha Khatwani
- Department of Pediatrics, Stuart M. Miller School of Medicine, Miami, FL, United States
- Natasha Khatwani
- Department of Microbiology & Immunology, Stuart M. Miller School of Medicine, Miami, FL, United States
- Natasha Khatwani
- Sheila and David Fuente Program in Cancer Biology, University of Miami, Miami, FL, United States
- Natasha Khatwani
- Program in Tumor Biology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States
- Rizwan Romee
- Division of Hematologic Neoplasia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
- Asha B. Pillai
- Department of Pediatrics, Stuart M. Miller School of Medicine, Miami, FL, United States
- Asha B. Pillai
- Department of Microbiology & Immunology, Stuart M. Miller School of Medicine, Miami, FL, United States
- Asha B. Pillai
- Sheila and David Fuente Program in Cancer Biology, University of Miami, Miami, FL, United States
- Asha B. Pillai
- Program in Tumor Biology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States
- DOI
- https://doi.org/10.3389/fimmu.2022.1004415
- Journal volume & issue
-
Vol. 13
Abstract
No abstracts available.Keywords
- innate immunity
- immunotherapy
- natural killer (Nk) cell
- natural killer T (NKT) cells
- gamma-delta (γ/δ) T lymphocytes
- macrophage
